PECAM1 and neoplasm: The efficacy of anti-IFN-γAb treatment was verified by analysis of MHCII protein expression in infiltrating CD11b+ cells, brain IgG staining (Figure 4—figure supplement 1a–b), and CD31+ cell density in the tumor area, as described below.